A recent open-label, single-arm, phase 2 study sought to assess evaluate an alternative dosing regimen for adults myelofibrosis (MF) to assess whether such a regimen could mitigate anemia.
While ruxolitinib is approved for twice-daily dosing to treat intermediate- or high-risk myelofibrosis (MF), anemia has been reported as an adverse event (AE) in more than 40% of patients in some clinical trials. Anemia in the early weeks of therapy may lead to treatment discontinuation, potentially leading to disease rebound.
A recent open-label, single-arm, phase 2 study sought to assess evaluate an alternative dosing regimen for adults with primary MF, postpolycythemia vera MF, or postessential thrombocythemia MF.
A total of 42 patients completed the study, and 37 completed a follow-up period. While prior therapies for MF were allowed, patients were required to discontinue all drugs to treat underlying MF before initiating ruxolitinib.
Patients were given ruxolitinib in oral doses of 5 mg tablets for 24 weeks. The starting dose for all patients was 10 mg twice per day, taken 12 hours apart. At weeks 12 and 18, doses could be increased by 5 mg twice per day in patients with lack of efficacy, and at any point, doses could be reduced for safety; if anemia was observed, doses could be dropped to 5 mg twice per day.
The study’s primary endpoint was the mean percentage change from baseline in spleen volume at week 24. Symptom severity was measured by the Myelofibrosis Symptom Assessment Form Total Symptom Score (MFSAF TSS).
The mean percentage reduction from baseline in spleen volume at weeks 12 and 24 was 16.3% (standard deviation [SD],12.4%) and 14.9% (SD, 21.1%), respectively.A dose-response relationship was observed, with week 24 mean spleen volume reductions of 20.1% (SD, 18.3%) and 32.9% (SD, 12.9%) among patients receiving average total daily doses of ruxolitinib or greater than 20 mg-30 mg and greater than 30mg-40 mg, respectively.
The mean baseline MFSAF TSS score was 16.6 (SD, 10.1), and this scored dropped with treatment; the mean score at weeks 6, 12, 18, and 24 was 10.5 (SD, 7.2), 10.0 (SD, 7.6), 8.4 (SD, 6.4), and 9.3 (SD, 8.0), respectively. At week 24, patients who were taking an average daily dose of more than  30 mg-40 mg had the greatest median percentage reduction from baseline in MFSAF TSSscore.
IN total, 93.3% of patients (n = 42) had a treatment-emergent AE. Anemia (26.7%) was the most commonly reported, followed by fatigue (22.2%) and arthralgia (20.0%). Seventeen patients (37.8%) had an AE of grade 3 or higher. One AE, myelodysplastic syndrome, led to treatment discontinuation and later death, and serious AEs were reported in 2 patients.
The authors concluded that, while treatment guidelines adhere to ruxolitinib’s dosing as described in its product label, dose escalation may be a feasible strategy for patients who have anemia or are likely to become anemic.
Reference
Talpaz M, Erickson-Viltanen S, Hou K, Hamburg S, Baer MR. Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study. J Hematolol Oncol. 2018; 11(1):101. doi: 10.1186/s13045-018-0642-0.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More